Based on the research available through Pillser, there is currently no direct evidence showing that Clostridium butyricum can help reduce the need for oxygen therapy in infants.

Here's what the research database does show about Clostridium butyricum:

• 10 studied health outcomes are recorded on Pillser, but none relate specifically to respiratory support, oxygen therapy, bronchopulmonary dysplasia (BPD), or neonatal respiratory outcomes in infants.
• The outcomes that have been studied include reduced inflammation, improved gut microbiota composition, reduced fever duration, reduced anxiety, and improved nutritional status — each based on a single study¹.

While Clostridium butyricum is a probiotic that produces butyrate (a short-chain fatty acid with anti-inflammatory properties), and some research has explored probiotics for preventing necrotizing enterocolitis or reducing inflammation in preterm infants, this specific question about reducing oxygen therapy needs is not supported by the available evidence in my databases.

Important: If you are asking about a real infant requiring oxygen therapy, please consult with a neonatologist or pediatric specialist. This is a critical medical situation that should be managed by qualified healthcare professionals.

Footnotes

1. Pillser research database, Clostridium butyricum. ↩